Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements

Area of Science:

• Public Health
• Epidemiology
• Vaccinology

Background:

• Invasive meningococcal disease (IMD) presents a substantial global health challenge, despite being vaccine-preventable.
• Annual global cases exceed one million, with case fatality rates between 10% and 40%.
• Survivors often face lifelong sequelae, impacting quality of life and incurring significant care costs.

Purpose of the Study:

• To present and discuss the conventional and under-recognized burdens associated with IMD.
• To highlight the need for a revised approach to measuring disease burden for accurate societal impact assessment.
• To inform cost-effectiveness analyses for vaccination programs.

Main Methods:

• Review of existing literature on IMD burden.
• Identification and categorization of both quantifiable and under-recognized disease impacts.
• Discussion of implications for public health policy and resource allocation.

Main Results:

• Conventional metrics often overlook significant long-term burdens like cognitive deficits, psychological stress, and familial impact.
• Financial burdens encompass acute treatment, follow-up care, and extensive public health resource strain during outbreaks.
• Under-recognized costs include adaptive measures for social reintegration and legal expenses.

Conclusions:

• Current cost-effectiveness analyses for IMD vaccination programs may underestimate the true societal cost.
• A comprehensive understanding of all disease burdens is necessary for informed public health decision-making.
• Revising measurement approaches is essential to fully grasp the societal consequences of IMD.